Show simple item record

dc.contributor.authorZhang, J
dc.contributor.authorDulak, AM
dc.contributor.authorHattersley, MM
dc.contributor.authorWillis, BS
dc.contributor.authorNikkilä, J
dc.contributor.authorWang, A
dc.contributor.authorLau, A
dc.contributor.authorReimer, C
dc.contributor.authorZinda, M
dc.contributor.authorFawell, SE
dc.contributor.authorMills, GB
dc.contributor.authorChen, H
dc.date.accessioned2020-05-19T13:40:55Z
dc.date.issued2018-07-12
dc.identifier.citationOncogene, 2018, 37 (28), pp. 3763 - 3777
dc.identifier.issn0950-9232
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3617
dc.identifier.eissn1476-5594
dc.identifier.doi10.1038/s41388-018-0194-3
dc.description.abstractPrevious reports have demonstrated that select cancers depend on BRD4 to regulate oncogenic gene transcriptional programs. Here we describe a novel role for BRD4 in DNA damage response (DDR). BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays an indispensable part in DNA replication checkpoint signaling. Inhibition of BRD4 by JQ1 or AZD5153 resulted in a rapid, time-dependent reduction in CHK1 phosphorylation and aberrant DNA replication re-initiation. Furthermore, BRD4 inhibition sensitized cancer cells to various replication stress-inducing agents, and synergized with ATR inhibitor AZD6738 to induce cell killing across a number of cancer cell lines. The synergistic interaction between AZD5153 and AZD6738 is translatable to in vivo ovarian cell-line and patient-derived xenograft models. Taken together, our study uncovers a new biological function of BRD4 and provides mechanistic rationale for combining BET inhibitors with DDR-targeted agents for cancer therapy.
dc.formatPrint-Electronic
dc.format.extent3763 - 3777
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectHumans
dc.subjectMice
dc.subjectMice, SCID
dc.subjectDNA Damage
dc.subjectSulfoxides
dc.subjectPiperazines
dc.subjectPyrimidines
dc.subjectHeterocyclic Compounds, 2-Ring
dc.subjectNuclear Proteins
dc.subjectTranscription Factors
dc.subjectXenograft Model Antitumor Assays
dc.subjectSignal Transduction
dc.subjectDNA Replication
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectPhosphorylation
dc.subjectFemale
dc.titleBRD4 facilitates replication stress-induced DNA damage response.
dc.typeJournal Article
dcterms.dateAccepted2018-02-05
rioxxterms.versionofrecord10.1038/s41388-018-0194-3
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncogene
pubs.issue28
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Biology and Genomic Instability
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Target Biology and Genomic Instability
pubs.publication-statusPublished
pubs.volume37
pubs.embargo.termsNot known
icr.researchteamTarget Biology and Genomic Instability
dc.contributor.icrauthorWang, Anderson


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record